Droplex KRAS Mutation Test v2

Detection of the 28 defined mutations within the KRAS oncogene

Features

Colorectal Cancer (CRC) is one of the cancers with the most incidents & mortality rate around the globe. KRAS mutation is the most common driver mutation in colorectal cancer patients which accounts about 30 ~ 40 % of total cases. KRAS G12C mutation is also an important mutation for Non-small Cell Lung Cancer (NSCLC) patients, which occurs in 13 % of all NSCLC cases. The CE-IVD certified Droplex KRAS Mutation Test v2 detects 28 defined mutations within the KRAS oncogene using Digital DropletTM Technology. This companion diagnostic test helps identify CRC and NSCLC patients who are eligible for tailored treatment.

BIOTYPE is the exclusive distributor of the Droplex Test Series in Germany. Legal manufacturer of the kits is GENCURIX, Inc.

Biomarkers

Exon 2: G12C/S/R/V/D/A, G13D

Exon 3: A59T/E/G, Q61K/E/P/R/L/H

Exon 4: K117E/R/N, A146P/S/T/G/V/I

Product specifications

  • Cat. No.
  • CD012
  • Cancer type
  • Colorectal Cancer, Non-Small Cell Lung Cancer
  • Regulatory status
  • CE-IVD
  • Compatible sample type
  • DNA from FFPE tissue, cfDNA from Plasma
  • Mutation variants
  • 28
  • Kit size/reactions
  • 24 samples/kit (4 well-reactions/sample)
  • Platform
  • Digital DropletTM PCR

Resources

Instructions for Use / Handbooks
No items found.
Instructions for Use / Handbooks
No items found.
Safety Data Sheets / Non-Hazardous Statements
No items found.
Non Hazardous Statements
No items found.
Technical Information
No items found.

Ordering Information

Droplex KRAS Mutation Test v2

Kit size: 24 samples/kit (4 well-reactions/sample)
Cat. No.: CD012
Status: CE-IVD

Product Request